Vimarsana
Biggest News Aggregation in the World

Giant Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Giant Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Giant Cell Today - Breaking & Trending Today

Giant Cell/Temporal Arteritis-Causes-Symptoms-Diagnosis-Treatment-Complications - Vimarsana News

Giant Cell/Temporal Arteritis-Causes-Symptoms-Diagnosis-Treatment-Complications

Giant Cell Arteritis (GCA) or Temporal Arteritis is a condition where arteries those supplying to the head region get inflamed. The causes of Temporal Arteritis are not known.

Brain Cells to Taste Buds Monitor Mindful Eating - Vimarsana News

Brain Cells to Taste Buds Monitor Mindful Eating

Brainstem recording of tastebud neurons reveals the process of overindulgence of food, opening new avenues for weight loss drugs.

Giant Cell/Temporal Arteritis-Causes-Symptoms-Diagnosis-Treatment-Complications - Vimarsana News

Giant Cell/Temporal Arteritis-Causes-Symptoms-Diagnosis-Treatment-Complications

Giant Cell Arteritis (GCA) or Temporal Arteritis is a condition where arteries those supplying to the head region get inflamed. The causes of Temporal Arteritis are not known.

Unique Giant Cancer Cells Found in Patients With Myelodysplastic Syndromes - Vimarsana News

Unique Giant Cancer Cells Found in Patients With Myelodysplastic Syndromes

Authors suggest the finding may indicate the cells play a role in hematological malignancies.

Source: ajmc.com
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus - Vimarsana News

Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary...